Search Result

Results for "

C3 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 17β-HSD (1) Aldose Reductase (4) Angiotensin Receptor (2) Antibiotic (3) Apoptosis (5) Arrestin (2) Autophagy (5) Bacterial (4) Bcl-2 Family (1) Calcium Channel (1) Complement System (10) COX (3) Cytochrome P450 (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (6) FABP (1) Ferroptosis (2) FGFR (2) Glucosylceramide Synthase (GCS) (1) Glutathione Reductase (1) Hedgehog (2) HIV (1) HSP (1) Influenza Virus (1) Isotope-Labeled Compounds (14) JAK (1) MicroRNA (58) Mitochondrial Metabolism (1) Mitophagy (1) Monoamine Oxidase (1) Oxidative Phosphorylation (1) Phosphatase (1) PI3K (2) PROTAC Linkers (2) PROTACs (1) Reactive Oxygen Species (4) SARS-CoV (4) Sirtuin (1) Sodium Channel (2) Toll-like Receptor (TLR) (3) Topoisomerase (1) Wee1 (1)
By Research Areas:	Cancer (40) Cardiovascular Disease (4) Endocrinology (1) Infection (6) Inflammation/Immunology (18) Metabolic Disease (8) Neurological Disease (7)
Click Chemistry:	Azide (1) Alkynes (1)

135

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1036

Compstatin 1 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 1 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-155716

G43-C3-TEG	Bacterial Glucosylceramide Synthase (GCS)	Infection
G43-C3-TEG is a glycosyl-transferase inhibitor. G43-C3-TEG reduces the biofilm formation by decreasing the production of EPS (extracellular polysaccharides) .

HY-153539

AP-C3	Others	Others
AP-C3 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 6.3. AP-C3 only weakly inhibits cGKII-dependent anion secretion .

HY-157510

Thalidomide-O-C3-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C3-azide is a click chemistry modification of the cereblon (CRBN) inhibitor Thalidomide (HY-14658). Thalidomide-O-C3-azide contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing alkyne groups. Thalidomide-O-C3-azide can be used as a ligand of E3 ubiquitin ligase and Linker conjugates (E3 Ligase Ligand-Linker Conjugates) for the synthesis of PROTACs .

HY-132295

Azenosertib

ZN-C3
Wee1 Cancer

Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC₅₀=3.9 nM). Azenosertib exhibits antitumor activity .
HY-150648

S07-2008

Others Cancer

S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC₅₀ of 0.16 μM. S07-2008 shows anticancer activities .

Azenosertib ZN-C3	Wee1	Cancer
Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC₅₀=3.9 nM). Azenosertib exhibits antitumor activity .

S07-2008	Others	Cancer
S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC₅₀ of 0.16 μM. S07-2008 shows anticancer activities .

HY-141893

3-Cyanovinylcarbazole phosphoramidite	DNA/RNA Synthesis	Infection
3-Cyanovinylcarbazole phosphoramidite is an antiviral agent that inhibits the synthesis of viral DNA. The modified nucleoside in the compound is synthesized by modifying the ribonucleotide with cyano group at the C-3 position, and can be used as a phosphoric acid amide for DNA synthesis .

HY-145255

Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH	PROTAC Linkers Toll-like Receptor (TLR)	Inflammation/Immunology
Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .

HY-P3204

POT-4 AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-153540

AP-C4	Others	Others
AP-C4 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 5.2. AP-C3 does not inhibit cGKII-dependent anion secretion .

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-150624

SARS-CoV-2 nsp13-IN-3	SARS-CoV	Infection
SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC₅₀ of 32 μM against nsp13 ssDNA ⁺ ATPase .

HY-P99050

Sutimlimab	Complement System	Cardiovascular Disease Inflammation/Immunology
Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase .

HY-P1717

AMY-101 Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate 2 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA 2 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-115902

FGFR4-IN-7	FGFR Apoptosis	Cancer
FGFR4-IN-7 (Compound C3) is a covalent reversible FGFR4 inhibitor with an IC₅₀ value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .

HY-125877

PROTAC Mcl1 degrader-1	PROTACs Bcl-2 Family	Cancer
PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC) based on Cereblon ligand, is a potently and selectively Mcl-1 (Bcl-2 family member) inhibitor with an IC₅₀ of 0.78 μM. PROTAC Mcl1 degrader-1 inhibits Bcl-2 with an IC₅₀ of 0.54 μM .

HY-163267

ZNL0325	Others	Others
ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-145253

Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH	PROTAC Linkers Toll-like Receptor (TLR)	Inflammation/Immunology
Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .

HY-145254

Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH	Toll-like Receptor (TLR)	Inflammation/Immunology
Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis .

HY-163032

FABP4-IN-3	FABP	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 K_i = 25 ± 3 ^a nM, FABP3 K_i = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P2141

TRV-120027 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-157810

AKR1C3-IN-11	Aldose Reductase	Cancer
AKR1C3-IN-11 (Compound 6e) is a Aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 2.0 μM. AKR1C3-IN-11 inhibit cell proliferation in combination with abiraterone (HY-70013). AKR1C3-IN-11 can be used for the research of prostate cancer .

HY-107379

AKR1C3-IN-1

Others Others

AKR1C3-IN-1 is a potent, highly selective inhibitor of AKR1C3, with an IC₅₀ of 13 nM.

AKR1C3-IN-1	Others	Others
AKR1C3-IN-1 is a potent, highly selective inhibitor of *AKR1C3, with an IC₅₀* of 13 nM.

HY-163323

AKR1C3-IN-12	Aldose Reductase	Cancer
AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .

HY-146574

AKR1C3-IN-7

Others Cancer

AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC₅₀ of 0.19 μM. AKR1C3-IN-7 shows antitumor activity .
HY-146575

AKR1C3-IN-8

Others Cancer

AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC₅₀ of 0.069 μM. AKR1C3-IN-8 shows antitumor activity .

AKR1C3-IN-7	Others	Cancer
AKR1C3-IN-7 (Compound 13) is a potent, selective *AKR1C3* inhibitor with an IC₅₀ of 0.19 μM. AKR1C3-IN-7 shows antitumor activity .

AKR1C3-IN-8	Others	Cancer
AKR1C3-IN-8 (Compound 5) is a potent, selective *AKR1C3* inhibitor with an IC₅₀ of 0.069 μM. AKR1C3-IN-8 shows antitumor activity .

HY-138557

AKR1C3-IN-4	17β-HSD	Cancer
AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research .

HY-155502

AKR1C3-IN-10

Aldose Reductase Cancer

AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC₅₀=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model .

AKR1C3-IN-10	Aldose Reductase	Cancer
AKR1C3-IN-10 (compound 5r) is a selective *AKR1C3* inhibitor (IC₅₀=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model .

HY-152188

AKR1C3-IN-9	Aldose Reductase	Cancer
AKR1C3-IN-9 is a selective inhibitor of Aldo-keto Reductase 1C3 (AKR1C3) with an IC₅₀ value of 8.92 nM. AKR1C3-IN-9 significantly reverses the Doxorubicin (HY-15142A) (DOX) resistance in a resistant breast cancer cell line .

HY-162266

C3TD879

Others Metabolic Disease

C3TD879 is a potent Type I kinase inhibitor. C3TD879 inhibits CITK catalytic activity with an IC₅₀ of 12 nM .

C3TD879	Others	Metabolic Disease
C3TD879 is a potent Type I kinase inhibitor. C3TD879 inhibits CITK catalytic activity with an IC₅₀ of 12 nM .

HY-146573

AKR1C3-IN-6	Others	Cancer
AKR1C3-IN-6 (Compound 1) is a potent, selective *AKR1C3* inhibitor with IC₅₀ values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity .

HY-155035

S07-1066	Others	Cancer
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells .

HY-19903

ASP-9521

1 Publications Verification

Others Cancer

ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC₅₀ of 11 nM for human AKR1C3.

ASP-9521 1 Publications Verification	Others	Cancer
ASP-9521 is a potent, selective and orally available *AKR1C3* inhibitor with an IC₅₀ of 11 nM for human AKR1C3.

HY-152189

S19-1035	Others	Cancer
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC₅₀ value of 3.04 nM. S19-1035 can be used for the research of tumor .

HY-144749

AKR1C3-IN-5	Others	Cancer
AKR1C3-IN-5 (Compound 6e) is a potent inhibitor of *AKR1C3. AKR1C3 enzyme is overexpressed in hormone-dependent prostate and breast tumors. AKR1C3-IN-5 derived from drupanin, which exhibits half-maximal inhibitory concentration (IC₅₀*) of 9.6 ± 3 μM and selectivity index (SI) of 5.5 against MCF-7 cells .

HY-12481A

SAR405 R enantiomer

Others Cancer

SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is a PIK3C3/Vps34 inhibitor.
HY-150646

S07-2009

Others Cancer

S07-2009 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ value of 0.20 μM .
HY-109154

Obafistat

Others Inflammation/Immunology

Obafistat is a potent aldo-keto reductase AKR1C3 inhibitor with an IC₅₀ of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4) .

SAR405 R enantiomer	Others	Cancer
SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is a PIK3C3/Vps34 inhibitor.

S07-2009	Others	Cancer
S07-2009 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ value of 0.20 μM .

Obafistat	Others	Inflammation/Immunology
Obafistat is a potent aldo-keto reductase *AKR1C3* inhibitor with an IC₅₀ of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4) .

HY-B0526S

Flumequine-13C3	Isotope-Labeled Compounds Bacterial Topoisomerase Antibiotic	Infection Cancer
Flumequine- ¹³C₃ is the ¹³C₃ labeled Flumequine. Flumequine (R-802) is a quinolone antibiotic, and acts as a topoisomerase II inhibitor, with an IC50 of 15 μM (3.92 μg/mL).

HY-14605BS

Rasagiline-13C3 mesylate racemic AGN1135-¹³C₃; TVP1012-¹³C₃ racemic	Isotope-Labeled Compounds Monoamine Oxidase	Neurological Disease
Rasagiline- ¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100683

A12B4C3	Phosphatase	Cancer
A12B4C3 is a potent human polynucleotide kinase/phosphatase (hPNKP) inhibitor with an IC₅₀ value of 0.06 μM. A12B4C3 has antiproliferative activity against cancer cells. A12B4C3 can also enhance the radiosensitivity of certain cancer cells .

HY-RI00006

hsa-let-7c-3p inhibitor	MicroRNA
hsa-let-7c-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-let-7c-3p inhibitor hsa-let-7c-3p inhibitor

HY-RI00333

hsa-miR-181c-3p inhibitor	MicroRNA
hsa-miR-181c-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-181c-3p inhibitor hsa-miR-181c-3p inhibitor

HY-RI00407

hsa-miR-200c-3p inhibitor	MicroRNA
hsa-miR-200c-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-200c-3p inhibitor hsa-miR-200c-3p inhibitor

HY-RI00717

hsa-miR-34c-3p inhibitor	MicroRNA
hsa-miR-34c-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-34c-3p inhibitor hsa-miR-34c-3p inhibitor

Cat. No.	Product Name	Target	Research Area

HY-P1398

Compstatin control peptide	Peptides	Inflammation/Immunology
Compstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor .

HY-P1036

Compstatin 1 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 1 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P3204

POT-4 AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-P1398A

Compstatin control peptide TFA	Peptides	Inflammation/Immunology
Compstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor .

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-P1717

AMY-101 Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate 2 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA 2 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P2141

TRV-120027 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) (TFA)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10361

Drupanin	Monophenols Classification of Application Fields Animals Source classification Phenols Disease Research Fields Cancer	Others
Drupanin is a compound isolated from green propolis. Drupanin can selectively inhibit the AKR1C3 enzyme. Drupanin has the potential for the research of breast cancer .

HY-N0376

Liquiritin 5 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Source classification Plants Monophenols Flavonoids Leguminosae Flavonones Phenols Inflammation/Immunology Disease Research Fields Glycyrrhiza uralensis Fisch.	Reactive Oxygen Species
Liquiritin, a flavonoid isolated from Glycyrrhiza uralensis, is a potent and competitive AKR1C1 inhibitor with IC₅₀s of 0.62 μM, 0.61 μM, and 3.72μM for AKR1C1, AKR1C2 and AKR1C3, respectively. Liquiritin efficiently inhibits progesterone metabolism mediated by AKR1C1 in vivo . Liquiritin acts as an antioxidant and has neuroprotective, anti-cancer and anti-inflammatory activity .

HY-121412

Lankacidin C	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Anticancer Disease Research Fields Other Antibiotics Cancer	Antibiotic Bacterial
Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity .

Cat. No.	Product Name	Chemical Structure

HY-B0526S

Flumequine-13C3
Flumequine- ¹³C₃ is the ¹³C₃ labeled Flumequine. Flumequine (R-802) is a quinolone antibiotic, and acts as a topoisomerase II inhibitor, with an IC50 of 15 μM (3.92 μg/mL).

HY-14605S

Rasagiline-13C3 mesylate
Rasagiline- ¹³C₃ ((R)-AGN1135- ¹³C₃; TVP1012- ¹³C₃) mesylateis the deuterium labeledRasagiline (mesylate)(HY-14605) . Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively .

HY-14605BS

Rasagiline-13C3 mesylate racemic

Rasagiline- ¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0166S4

L-Ascorbic acid-13C-3
L-Ascorbic acid- ¹³C-3 is the ¹³C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen

HY-N0898S

Catechin-13C3

Catechin- ¹³C₃ is the ¹³C-labeled Catechin. Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM.

HY-B0495S

Lamotrigine-13C3,d3
Lamotrigine- ¹³C₃,d₃ is the ¹³C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[1][2].

HY-12542S

Dantrolene-13C3

Dantrolene- ¹³C₃ is the ¹³C₃ labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

HY-40354S

Tofacitinib-13C3

Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-N0356S

(+/-)-Catechin Gallate-13C3
(+/-)-Catechin Gallate- ¹³C₃ is the ¹³C-labeled (-)-Catechin gallate. (-)-Catechin gallate is a minor constituent in green tea catechins. (-)-Catechin gallate inhibits the activity of COX-1 and COX-2 enzymes.

HY-N0060S1

Ferulic acid-13C3
Ferulic acid- ¹³C₃ is the ¹³C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-W770183

Uric acid-13C3
Uric acid- ¹³C₃ is ¹³C-labeled Uric acid (HY-B2130). Uric acid is the end product of purine metabolism in the human body. Uric acid can scavenge reactive oxygen species (ROS), such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation.

HY-N0001S

(±)-Epicatechin-13C3
(±)-Epicatechin- ¹³C₃ is the ¹³C labeled (±)-Epicatechin. (-)-Epicatechin (HY-N0001) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB[1].

HY-N7091S1

Atrazine-13C3,15N3
Atrazine- ¹³C₃, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Atrazine. Atrazine is principally used for control of certain annual broadleaf and grass weeds. Atrazine inhibits photophosphorylation but typically does not result in lethality or permanent cell damage in the short term[1].

HY-13632S1

Exemestane-13C3
Exemestane- ¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-B0150S1

Nicotinamide-15N,13C3
Nicotinamide- ¹⁵N, ¹³C₃ is the ¹³C-labeled and ¹⁵N-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.

HY-B0510S3

Trimethoprim-13C3

Trimethoprim- ¹³C₃is the deuterium labeledTrimethoprim(HY-B0510) . Trimethoprim is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim can inhibit infection of Influenza A virus in chick embryo when combinated with zinc .

HY-B0495S4

Lamotrigine-13C3
Lamotrigine- ¹³C₃ is the ¹³C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[1][2].

HY-13653S

(+/-)-Epigallocatechin Gallate-13C3

(+/-)-Epigallocatechin Gallate- ¹³C₃ is the ¹³C-labeled (-)-Epigallocatechin Gallate. (-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit EGFR signaling and thereby exert anticancer effects[1]. (-)-Epigallocatechin Gallate (EGCG) is a glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) inhibitor. Epigallocatechin-3-gallate induces oxidative phosphorylation (OXPHOS) by activating cytochrome c oxidase.

HY-18085S2

Quercetin-13C3
Quercetin- ¹³C₃ is the ¹³C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

HY-B1075AS

(Rac)-Fosfomycin (benzylamine)-13C3

(Rac)-Fosfomycin (benzylamine)- ¹³C₃ is the ¹³C labeled Fosfomycin[1]. Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[2][3].